Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Permenergosbyt reported for 3 months of 2025 by RAS

4/29/25 PMSB

Severstal reported for the 3 months of 2025 by RAS

4/29/25 CHMF

Pharmacy Chain 36.6 reported for 2024 by IFRS

4/29/25 APTK

MMK will not pay final dividends for 2024

4/29/25 MAGN

Ozon reported for 3 months of 2025 by IFRS

4/29/25 OZON

Ozon's turnover in Q1 increased by 47%

4/29/25 OZON

MGKL will place convertible bonds

4/29/25 MGKL

MMK-METIZ reported for 3 months of 2025 by RAS

4/28/25 MMMZ

T Plus reported for 2024 under IFRS

4/28/25 VTGK

Moscow Exchange launched over-the-counter trading in blocked shares from the U.S.

4/28/25 MOEX